Isolated Antibody to Hepatitis B Core Antigen in Individuals Infected with HIV-1
Sir-We read with interest the article by Gandhi et al. [1] concerning the factors associated with the presence of isolated antibody to hepatitis B core antigen (antiHBc) in patients with human immunodeficiency virus type 1 (HIV-1) infection. Patients in this study who were seronegative for hepatitis B surface antigen (HBsAg) and for antibody to HBsAg (antiHBs) had a relatively higher CD4 + cell count (median, ∼350 cells/mm 3 ) and lower plasma virus load (median, р3.75 log 10 copies/mL) than patients who were not; 42% of these 142 patients had a history of percutaneous exposure to blood. In order to determine whether the prevalence of isolated anti-HBc might be different among patients who had acquired HIV infection mainly through sexual transmission and who were at a late stage of HIV infection, we analyzed the data in a prospective observational study of 716 nonhemophiliac patients infected with HIV-1, aged у15 years, in an area where hepatitis B (HBV) infection is hyperendemic [2, 3] . All statistical analyses were performed using SAS statistical software (Version 8.02, SAS Institute). Categorical variables were compared using x 2 or Fisher's exact test, whereas noncategorical variables were compared using Wilcoxon's rank-sum test. The Spearman correlation coefficient was used to compute the relationship between ordinal and continuous variables.
Of the 716 patients enrolled in our study between June 1994 and June 2002, 416 (58.1%) had a complete diagnostic study of hepatitis B status (i.e., the presence of HBsAg, anti-HBs, and anti-HBc) performed at enrollment. Their clinical characteristics are shown in table 1 (overleaf). Most of them were at the late stage of HIV infection, with a depleted CD4 cell count and a high plasma virus load (PVL), and had acquired HIV infection through sexual transmission; only 2.4% of the patients had a history of exposure to blood. Approximately 10% of our patients had chronic hepatitis C virus (HCV) infection. Of the 416 patients who had a complete study diagnostic study of hepatitis B status performed, 140 (33.7%) were negative for HBsAg and anti-HBs; isolated anti-HBc was detected in 113 patients (80.7%). The prevalence of isolated anti-HBc appeared to increase with the severity of immunosuppression (Spearman correlation coefficient, Ϫ0.84; ) (table 1) . In a P p .07 multivariate analysis, we did not find that either chronic HCV infection or a history of exposure to blood was associated with presence of isolated anti-HBc (data not shown), which finding may be related to the small number of patients with chronic HCV infection in our study. In addition, isolated anti-HBc was not associated with an increased risk for mortality or with progression of HIV infection either before or after the introduction of HAART.
Our findings suggest that the prevalence of isolated anti-HBc will vary with the epidemiologic characteristics of the patients enrolled in the study and the background seroprevalence of HBV infection. In an area of hyperendemicity of HBV infection and low endemicity of HCV infection, the prevalence of isolated anti-HBc will be high among patients at a late stage of HIV infection. .26
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NOTE. Data are no. or no. (%) of patients, unless indicated otherwise. Group 1 is defined as patients who are seropositive for hepatitis B surface antigen (HBsAg), seronegative for antibody to hepatitis B surface antigen (anti-HBs), and seropositive for antibody to hepatitis B core antigen (anti-HBc). Group 2 is defined as patients who are seronegative for HBsAg, seropositive for anti-Hbs, and seropositive for anti-HBc. Group
